A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND 70,058.

Trial Profile

A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND 70,058.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2017

At a glance

  • Drugs Fenretinide (Primary) ; Cytarabine; Hydrocortisone; Methotrexate
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 22 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018.
    • 13 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top